Company intelligence / Profile preview

Summa Therapeutics

Cambridge, Massachusetts, United Statessummatherapeutics.com ↗

Ownership: Private
Development stage: Commercial

Overview

Summa Therapeutics has developed and launched the Finesse BTK Multicath, a multifunctional, FDA-cleared injectable angioplasty balloon catheter designed to streamline complex below-the-knee interventional procedures. Early clinical use has demonstrated improved procedural efficiency, reduced equipment needs, lower contrast usage, and high-quality imaging. The device is positioned to become standard of care for PAD patients at high risk of limb loss or kidney injury from traditional contrast agents.

Therapeutic areas: CardiovascularNephrology
Modalities: DeviceCatheter-based therapyAngioplasty balloon catheter (multifunctional)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Finesse BTK Multicath

Commercial

Indications: Peripheral arterial disease

Beyond the preview

Go deeper on Summa Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Summa Therapeutics.

Explore the full profile